Protein partnership may fend off pancreatic cancer progression

Targeting FGFR2 may prevent or delay some KRAS-mutated pancreatic cancers

Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein, and FGFR2 inactivation delayed KRAS-mutated PDAC development in mice, according to results of a study published in Cancer Research, a journal of the American Association for Cancer Research.

April 04, 2025

Vol.51 No.13

Drugs & Targets

FDA approves cabozantinib for patients 12 and up with pNET and epNET

FDA approved cabozantinib (Cabometyx) for adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors and well-differentiated extra-pancreatic neuroendocrine tumors.

March 28, 2025

Vol.51 No.12

Clinical Roundup

KRAS mutation is a significant predictor of metastasis and survival in pancreatic cancer, study shows

A new study by Mayo Clinic Comprehensive Cancer Center researchers found that the presence of a specific genetic mutation—KRAS circulating tumor DNA—strongly indicates a higher risk of cancer spread and worse survival rates for patients with pancreatic ductal adenocarcinoma.

March 21, 2025

Vol.51 No.11

Clinical Roundup

Immunovia completes second clinical validation of next-gen pancreatic cancer test

Immunovia announced results from the VERIFI study, the second clinical validation study of its next-generation pancreatic cancer test.

March 21, 2025

Vol.51 No.11

Funding Opportunities

The Stephenson Global Prize and Stephenson Global Scholar Grants calls for nominations, letters of intent

The Stephenson Global Pancreatic Cancer Research Institute, established to advance early detection, innovative treatments, and groundbreaking research for pancreatic cancer, has launched a call for nominations and Letters of Intent for two award opportunities.

March 14, 2025

Vol.51 No.10

Black History Month Conversation with The Cancer Letter

Shearwood McClelland III: “When you stand for something, you’re always going to be attacked.”

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States. Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

February 28, 2025

Vol.51 No.08

By Jacquelyn Cobb